GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » PB Ratio

Biomerica (Biomerica) PB Ratio : 1.29 (As of May. 13, 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-13), Biomerica's share price is $0.60. Biomerica's Book Value per Share for the quarter that ended in Feb. 2024 was $0.46. Hence, Biomerica's PB Ratio of today is 1.29.

The historical rank and industry rank for Biomerica's PB Ratio or its related term are showing as below:

BMRA' s PB Ratio Range Over the Past 10 Years
Min: 0.93   Med: 4.66   Max: 21.34
Current: 1.3

During the past 13 years, Biomerica's highest PB Ratio was 21.34. The lowest was 0.93. And the median was 4.66.

BMRA's PB Ratio is ranked better than
73.05% of 794 companies
in the Medical Devices & Instruments industry
Industry Median: 2.23 vs BMRA: 1.30

During the past 12 months, Biomerica's average Book Value Per Share Growth Rate was 4.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -16.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 8.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -0.40% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biomerica was 52.50% per year. The lowest was -34.50% per year. And the median was -7.30% per year.

Back to Basics: PB Ratio


Biomerica PB Ratio Historical Data

The historical data trend for Biomerica's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica PB Ratio Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.47 5.36 4.87 5.41 1.97

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 1.97 2.00 1.67 2.63

Competitive Comparison of Biomerica's PB Ratio

For the Medical Devices subindustry, Biomerica's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomerica's PB Ratio falls into.



Biomerica PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Biomerica's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Feb. 2024)
=0.60/0.464
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Biomerica  (NAS:BMRA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Biomerica PB Ratio Related Terms

Thank you for viewing the detailed overview of Biomerica's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663